{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:22:12Z","timestamp":1789924932683,"version":"4.0.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Editor\u2019s Perspective<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>What We Already Know about This Topic<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>What This Article Tells Us That Is New<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Central pain sensitization is often refractory to drug treatment. Dextromethorphan, an\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -methyl-\n                      <jats:sc>d<\/jats:sc>\n                      -aspartate receptor antagonist, is antihyperalgesic in preclinical pain models. The hypothesis is that dextromethorphan is also antihyperalgesic in humans.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This randomized, double-blind, placebo-controlled, crossover study explores the antihyperalgesic effect of single and repeated 30-mg dose of oral dextromethorphan in 20 volunteers, using the freeze-injury pain model. This model leads to development of primary and secondary hyperalgesia, which develops away from the site of injury and is associated with central sensitization and activation of\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -methyl-\n                      <jats:sc>d<\/jats:sc>\n                      -aspartate receptor in the spinal cord. The primary outcome was antihyperalgesia calculated with the area under the curve of the percentage change in mechanical pain threshold (electronic von Frey) on the area of secondary hyperalgesia. The secondary outcomes were mechanical pain threshold on the area of primary hyperalgesia and cognitive (reaction time) effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Single 30-mg results are reported. Antihyperalgesia (% \u00b7 min) is significantly higher on the area of secondary hyperalgesia with dextromethorphan than placebo (median [interquartile range]: 3,029 [746; 6,195]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 710 [\u20133,248; 4,439],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009, Hedge\u2019s g = 0.8, 95% CI [0.1; 1.4]). On primary hyperalgesia area, mechanical pain threshold 2 h after drug intake is significantly higher with dextromethorphan (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011, Hedge\u2019s g = 0.63, 95% CI [0.01; 1.25]). No difference in antinociception is observed after thermal painful stimuli on healthy skin between groups. Reaction time (ms) is shorter with placebo than with dextromethorphan (median [interquartile range]: 21.6 [\u201337.4; 0.1]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . \u20131.2 [\u201324.3; 15.4],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015, Hedge\u2019s g = 0.75, 95% CI [0.12; 1.39]). Nonserious adverse events occurrence (15%, 3 of 20 volunteers) was similar in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study shows that low-dose (30-mg) dextromethorphan is antihyperalgesic in humans on the areas of primary and secondary hyperalgesia and reverses peripheral and central neuronal sensitization. Because dextromethorphan had no intrinsic antinociceptive effect in acute pain on healthy skin,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -methyl-\n                      <jats:sc>d<\/jats:sc>\n                      -aspartate receptor may need to be sensitized by pain for dextromethorphan to be effective.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aln.0000000000002736","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T07:23:15Z","timestamp":1557991395000},"page":"356-368","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Dextromethorphan Analgesia in a Human Experimental Model of Hyperalgesia"],"prefix":"10.1097","volume":"131","author":[{"given":"E.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Decleves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Labat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ducheix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dual\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20241223","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: A systematic review of epidemiological studies.","volume":"155","year":"2014","journal-title":"Pain"},{"key":"R3-20241223","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","article-title":"Central sensitization: A generator of pain hypersensitivity by central neural plasticity.","volume":"10","year":"2009","journal-title":"J Pain"},{"key":"R4-20241223","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archneur.60.11.1524","article-title":"Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations.","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"R5-20241223","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/15563650.2011.585429","article-title":"Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000-2010.","volume":"49","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"key":"R6-20241223","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/fcp.12076","article-title":"Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain.","volume":"28","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"R7-20241223","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.0001-5172.2004.0325.x","article-title":"Analgesic effect of dextromethorphan in neuropathic pain.","volume":"48","year":"2004","journal-title":"Acta Anaesthesiol Scand"},{"key":"R8-20241223","first-page":"45","article-title":"Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.","volume":"16","year":"2013","journal-title":"Pain Physician"},{"key":"R9-20241223","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1526-4637.2011.01316.x","article-title":"Efficacy and safety of dextromethorphan\/quinidine at two dosage levels for diabetic neuropathic pain: A double-blind, placebo-controlled, multicenter study.","volume":"13","year":"2012","journal-title":"Pain Med"},{"key":"R10-20241223","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1245\/ASO.2003.08.007","article-title":"Dextromethorphan mitigates phantom pain in cancer amputees.","volume":"10","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"R11-20241223","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.55.7.964","article-title":"A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias.","volume":"55","year":"2000","journal-title":"Neurology"},{"key":"R12-20241223","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cct.2015.01.012","article-title":"Rationale and design of a randomized double-blind clinical trial in breast cancer: Dextromethorphan in chemotherapy-induced peripheral neuropathy.","volume":"41","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"R13-20241223","first-page":"385","article-title":"Different patterns of hyperalgesia induced by experimental inflammation in human skin.","volume":"117 (Pt 2)","year":"1994","journal-title":"Brain"},{"key":"R14-20241223","first-page":"56","article-title":"Neural mechanisms of hyperalgesia after tissue injury.","volume":"26","year":"2005","journal-title":"Johns Hopkins Apl Tech Dig"},{"key":"R15-20241223","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/0024-3205(84)90121-8","article-title":"Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes.","volume":"34","year":"1984","journal-title":"Life Sci"},{"key":"R16-20241223","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0009-9236(96)90056-9","article-title":"The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.","volume":"60","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R17-20241223","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.lfs.2005.04.025","article-title":"Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil.","volume":"77","year":"2005","journal-title":"Life Sci"},{"key":"R18-20241223","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2008.01.007","article-title":"Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice.","volume":"95","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R19-20241223","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans.","volume":"70","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R20-20241223","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.drugalcdep.2012.08.025","article-title":"Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.","volume":"128","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R21-20241223","first-page":"537","article-title":"Dextromethorphan withdrawal and dependence syndrome.","volume":"107","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"R22-20241223","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/0024-3205(91)90150-A","article-title":"Mu receptor binding of some commonly used opioids and their metabolites.","volume":"48","year":"1991","journal-title":"Life Sci"},{"key":"R23-20241223","first-page":"1263","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception.","volume":"274","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-20241223","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","article-title":"Pharmacology of dextromethorphan: Relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use.","volume":"164","year":"2016","journal-title":"Pharmacol Ther"},{"key":"R25-20241223","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/bja\/aeg178","article-title":"Effect site concentrations of remifentanil and pupil response to noxious stimulation.","volume":"91","year":"2003","journal-title":"Br J Anaesth"},{"key":"R26-20241223","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bcp.13018","article-title":"A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.","volume":"82","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R27-20241223","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2125.2006.02582.x","article-title":"Hyperalgesia induced by cutaneous freeze injury for testing analgesics in healthy volunteers.","volume":"61","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20241223","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis.","volume":"9","year":"2012","journal-title":"Nat Methods"},{"key":"R29-20241223","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences.","volume":"60","year":"1997","journal-title":"Am J Hum Genet"},{"key":"R30-20241223","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00008571-199608000-00008","article-title":"PCR-based genotyping for duplicated and deleted CYP2D6 genes.","volume":"6","year":"1996","journal-title":"Pharmacogenetics"},{"key":"R31-20241223","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2125.2002.01602.x","article-title":"Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers.","volume":"53","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R32-20241223","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00000542-200205000-00005","article-title":"Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials.","volume":"96","year":"2002","journal-title":"Anesthesiology"},{"key":"R33-20241223","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00115550-199924060-00005","article-title":"NMDA receptors and pain\u2013Hopes for novel analgesics.","volume":"24","year":"1999","journal-title":"Reg Anesth Pain Med"},{"key":"R35-20241223","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0301-0082(92)90027-C","article-title":"Peripheral and central mechanisms of cutaneous hyperalgesia.","volume":"38","year":"1992","journal-title":"Prog Neurobiol"},{"key":"R36-20241223","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.brainresrev.2008.12.009","article-title":"Descending control of nociception: Specificity, recruitment and plasticity.","volume":"60","year":"2009","journal-title":"Brain Res Rev"},{"issue":"suppl 5","key":"R37-20241223","first-page":"S62","article-title":"Dextromethorphan: Cellular effects reducing neuronal hyperactivity.","volume":"35","year":"1994","journal-title":"Epilepsia"},{"key":"R38-20241223","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1673-5374.153686","article-title":"A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases.","volume":"10","year":"2015","journal-title":"Neural Regen Res"},{"key":"R39-20241223","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.00950-10","article-title":"Dextromethorphan efficiently increases bactericidal activity, attenuates inflammatory responses, and prevents group a streptococcal sepsis.","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-20241223","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2004.11.015","article-title":"Intravenous dextromethorphan to human volunteers: Relationship between pharmacokinetics and anti-hyperalgesic effect.","volume":"113","year":"2005","journal-title":"Pain"},{"key":"R41-20241223","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0091-3057(95)00106-7","article-title":"An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist.","volume":"52","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"R42-20241223","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cell.2009.04.019","article-title":"Dissociation of the opioid receptor mechanisms that control mechanical and heat pain.","volume":"137","year":"2009","journal-title":"Cell"},{"issue":"1 suppl","key":"R43-20241223","first-page":"S26","article-title":"Abuse potential of morphine\/dextromethorphan combinations.","volume":"19","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"R44-20241223","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jat\/33.2.99","article-title":"Five deaths resulting from abuse of dextromethorphan sold over the internet.","volume":"33","year":"2009","journal-title":"J Anal Toxicol"},{"key":"R45-20241223","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2125.1992.tb04087.x","article-title":"Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.","volume":"33","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R46-20241223","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s002139900334","article-title":"Comparison of the antidepressants reboxetine, fluvoxamine and amitriptyline upon spontaneous pupillary fluctuations in healthy human volunteers.","volume":"149","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R47-20241223","first-page":"129","article-title":"Miotic action of tramadol is determined by CYP2D6 genotype.","volume":"56","year":"2007","journal-title":"Physiol Res"},{"key":"R48-20241223","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.nut.2010.08.003","article-title":"Validation of reaction time as a measure of cognitive function and quality of life in healthy subjects and patients.","volume":"27","year":"2011","journal-title":"Nutrition"},{"key":"R49-20241223","first-page":"75","article-title":"Antitussives and substance abuse.","volume":"4","year":"2013","journal-title":"Subst Abuse Rehabil"}],"container-title":["Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.asahq.org\/anesthesiology\/article-pdf\/131\/2\/356\/379384\/20190800_0-00025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/anesthesiology.pubs.asahq.org\/article.aspx?volume=131&page=356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:30Z","timestamp":1784899050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ALN.0000000000002736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aln.0000000000002736","relation":{},"ISSN":["0003-3022"],"issn-type":[{"value":"0003-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}